Advaxis, Inc.: Independent Data Safety Monitoring Board Gives “Go-Ahead” to Complete Dosing in First Leg of Advaxis’ Phase II Cervical Dysplasia Trial

(BUSINESS WIRE)--The science team from Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, met with the Data Safety Monitoring Board (DSMB), an independent group of medical experts, yesterday and received approval to dose all remaining patients in the initial forty (40) patient leg of the 120-patient, cervical dysplasia clinical trial being conducted in the United States.

MORE ON THIS TOPIC